Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 14/20 | 0.53 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1778173 | 0.85 | MCHR1 (0.49) | MCHR1DPP4 | |
| SCHEMBL1779303 | 0.82 | MCHR1 (0.77) | MCHR1DPP4KCNH2DPP8DPP9 | |
| SCHEMBL25604509 | 0.82 | MCHR1 (0.49) | MCHR1DPP4PDE1BKCNH2DPP8 | |
| SCHEMBL1781466 | 0.82 | MCHR1 (0.36) | MCHR1PDE1BKCNH2 | |
| SCHEMBL1782082 | 0.82 | MCHR1 (0.49) | MCHR1DPP4 | |
| SCHEMBL1781265 | 0.81 | MCHR1 (0.48) | MCHR1DPP4 | |
| SCHEMBL1781603 | 0.80 | MCHR1 (0.55) | MCHR1DPP4KCNH2DPP8DPP9 | |
| SCHEMBL1779387 | 0.80 | MCHR1 (0.55) | MCHR1DPP4KCNH2DPP8DPP9 | |
| SCHEMBL1780431 | 0.80 | MCHR1 (0.55) | MCHR1DPP4KCNH2DPP8DPP9 | |
| SCHEMBL1781974 | 0.79 | MCHR1 (0.49) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11680056-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680056-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20220402892-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED | 2011-05-19 | — | — | US | disclosed |
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED | 2011-05-19 | — | — | US | disclosed |
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED | 2011-05-19 | — | — | US | disclosed |
| WO-2009076387-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | MCHR1 4509/4885DPP4 2449/4885PDE1B 1236/4885 |
| US-11680056-B2 | MK2 inhibitors and uses thereof | MKNK2, ENPP2, MAPKAPK2 | MCHR1 4509/4885DPP4 2449/4885PDE1B 1236/4885 |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | MCHR1 4509/4885DPP4 2449/4885PDE1B 1236/4885 |
| US-20220402892-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | MCHR1 4467/4885DPP4 2154/4885PDE1B 1063/4885 |
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | MCHR1, MCHR2, MC1R | MCHR1 1/4885DPP4 504/4885PDE1B 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.